keyword
MENU ▼
Read by QxMD icon Read
search

Breast cancer in young

keyword
https://www.readbyqxmd.com/read/28634667/elevated-interleukin-13-receptor-alpha-1-expression-in-tumor-cells-is-associated-with-poor-prognosis-in-patients-with-invasive-breast-cancer
#1
Min Hui Park, Hee Jung Kwon, Jae-Ryong Kim, Byungheon Lee, Soo Jung Lee, Young Kyung Bae
BACKGROUND: Interleukin (IL)-13 is an immunoregulatory, anti-inflammatory cytokine that is produced by numerous immune cells, and plasma membrane receptor for IL-13 (IL-13R) is known to be expressed in various human malignancies and in immune cells. METHODS: The authors evaluated the expression of IL-13R alpha 1 (IL-13Rα1, an IL-13R subtype) by immunohistochemistry in tissue microarrays of 1213 invasive breast cancer (IBC) samples to determine the prognostic value of IL-13Rα1 expression...
June 20, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/28630300/g9a-drives-hypoxia-mediated-gene-repression-for-breast-cancer-cell-survival-and-tumorigenesis
#2
Francesco Casciello, Fares Al-Ejeh, Greg Kelly, Donal J Brennan, Shin Foong Ngiow, Arabella Young, Thomas Stoll, Karolina Windloch, Michelle M Hill, Mark J Smyth, Frank Gannon, Jason S Lee
G9a is an epigenetic regulator that methylates H3K9, generally causing repression of gene expression, and participates in diverse cellular functions. G9a is genetically deregulated in a variety of tumor types and can silence tumor suppressor genes and, therefore, is important for carcinogenesis. Although hypoxia is recognized to be an adverse factor in tumor growth and metastasis, the role of G9a in regulating gene expression in hypoxia has not been described extensively. Here, we show that G9a protein stability is increased in hypoxia via reduced proline hydroxylation and, hence, inefficient degradation by the proteasome...
June 19, 2017: Proceedings of the National Academy of Sciences of the United States of America
https://www.readbyqxmd.com/read/28628363/efficacy-of-a-weight-loss-intervention-for-african-american-breast-cancer-survivors
#3
Melinda Stolley, Patricia Sheean, Ben Gerber, Claudia Arroyo, Linda Schiffer, Anjishnu Banerjee, Alexis Visotcky, Giamila Fantuzzi, Desmona Strahan, Lauren Matthews, Roxanne Dakers, Cynthia Carridine-Andrews, Katya Seligman, Sparkle Springfield, Angela Odoms-Young, Susan Hong, Kent Hoskins, Virginia Kaklamani, Lisa Sharp
Purpose African American women with breast cancer have higher cancer-specific and overall mortality rates. Obesity is common among African American women and contributes to breast cancer progression and numerous chronic conditions. Weight loss interventions among breast cancer survivors positively affect weight, behavior, biomarkers, and psychosocial outcomes, yet few target African Americans. This article examines the effects of Moving Forward, a weight loss intervention for African American breast cancer survivors (AABCS) on weight, body composition, and behavior...
June 19, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28627650/the-inhibitory-effects-of-deep-sea-water-on-doxorubicin%C3%A2-induced-epithelial-mesenchymal-transition
#4
So-Young Chun, Soyoung Kim, Kyung-Soo Nam
It has been revealed that the induction of epithelial‑mesenchymal transition (EMT) is associated with drug resistance, leading to tumor recurrence and metastasis. Recent studies have shown that chemotherapeutic agents, besides their therapeutic effects, can induce EMT and enhance invasive and metastatic properties of tumor cells. Previously, we revealed that deep-sea water (DSW) exhibited antimetastatic effects in several human cancer cell lines. In the present study, we investigated the effects of DSW on doxorubicin-induced EMT in MCF-7 human breast cancer cells...
June 16, 2017: Oncology Reports
https://www.readbyqxmd.com/read/28624063/acceptance-of-adjuvant-chemotherapy-recommendations-in-early-stage-hormone-positive-breast-cancer
#5
Emily F Marcinkowski, Rebecca Ottesen, Joyce Niland, Courtney Vito
BACKGROUND: The role of systemic chemotherapy in early-stage, estrogen receptor (ER)-positive, and Her2-negative breast cancer remains an area of active investigation. The decision to recommend chemotherapy is multifactorial, and some patients decline recommended chemotherapy. We sought to identify patient factors leading to refusal of adjuvant therapy. MATERIALS AND METHODS: Data were collected from National Comprehensive Cancer Network Outcomes database and used to identify patients with primary, unilateral, T1-T2, N0, ER+, Her2-disease diagnosed from 2005-2011...
June 15, 2017: Journal of Surgical Research
https://www.readbyqxmd.com/read/28621227/expression-of-epithelial-mesenchymal-transition-driver-brachyury-and-status-of-tumor-infiltrating-cd8-and-foxp3-lymphocytes-in-predicting-treatment-responses-to-neoadjuvant-chemotherapy-of-breast-cancer
#6
Kwan Ho Lee, Eun Young Kim, Yong Lai Park, Sung-Im Do, Seoung Wan Chae, Chan Heun Park
Brachyury has been characterized as a driver of epithelial-mesenchymal transition process which is regarded as an important mechanism of cancer cell invasion and metastatic progression. The status of tumor-infiltrating lymphocytes has been proposed to predict response to neoadjuvant chemotherapy in breast cancer. We investigated the clinical significance and value of tumor-infiltrating lymphocytes and brachyury as biomarkers to predict treatment responses to neoadjuvant chemotherapy in breast cancer. We also examined the correlation of the Neo-Bioscore with tumor-infiltrating lymphocytes and brachyury to indirectly predict long-term outcome...
June 2017: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
https://www.readbyqxmd.com/read/28616237/higher-serum-concentrations-of-vimentin-and-dakp1-are-associated-with-aggressive-breast-tumour-phenotypes-in-ghanaian-women
#7
Benjamin Arko-Boham, Justice Tanihu Lomotey, Emmanuel Nomo Tetteh, Emmanuel Ayitey Tagoe, Nii Ayite Aryee, Ewurama Ampadu Owusu, Isaac Okai, Richard Michael Blay, Joe-Nat Clegg-Lamptey
BACKGROUND: Breast cancer, the most commonly diagnosed cancer among women and leading cause of cancer-related deaths worldwide, exhibits aggressive behavior in indigenous African women evidenced by high histologic grade tumours with low hormone receptor positivity. Aggressive breast cancers grow quickly, easily metastasize and recur and often have unfavourable outcomes. The current study investigated candidate genes that may regulate tumour aggression in Ghanaian women. We hypothesize that increased expression and function of certain genes other than the widely-held view attributing breast cancer aggression in African populations to their younger population age may be responsible for the aggressive nature of tumours...
2017: Biomarker Research
https://www.readbyqxmd.com/read/28615672/reconstruction-of-pathway-modification-induced-by-nicotinamide-using-multi-omic-network-analyses-in-triple-negative-breast-cancer
#8
Ji Young Kim, Hyebin Lee, Jongmin Woo, Wang Yue, Kwangsoo Kim, Seongmin Choi, Ja-June Jang, Youngsoo Kim, In Ae Park, Dohyun Han, Han Suk Ryu
Triple negative breast cancer (TNBC) is characterized by an aggressive biological behavior in the absence of a specific target agent. Nicotinamide has recently been proven to be a novel therapeutic agent for skin tumors in an ONTRAC trial. We performed combinatory transcriptomic and in-depth proteomic analyses to characterize the network of molecular interactions in TNBC cells treated with nicotinamide. The multi-omic profiles revealed that nicotinamide drives significant functional alterations related to major cellular pathways, including the cell cycle, DNA replication, apoptosis and DNA damage repair...
June 14, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28612617/-breast-cancer-in-young-women-correlation-of-clinical-histomorphological-and-molecular-genetic-features-of-breast-carcinoma-in-women-younger-than-35-years-of-age
#9
A Metelková, A Skálová, J Fínek
BACKGROUND: Worldwide, breast cancer is the leading type of malignancy in women. For premenopausal women, the disease brings much higher risk as it is usually more aggressive with worse prognosis. PATIENTS AND METHODS: In this retrospective study, 92 women treated at the Department of Oncology and Radiotherapy in Pilsen were selected from a basic cohort of 356 women under 35 years of age with breast cancer who were diagnosed between 2006 and 2015. The control group comprised 100 postmenopausal women over 65 years of age who were treated for invasive breast cancer...
2017: Klinická Onkologie: Casopis Ceské a Slovenské Onkologické Spolecnosti
https://www.readbyqxmd.com/read/28612595/trends-in-female-breast-cancer-by-age-group-in-the-chiang-mai-population
#10
Patumrat Sripan, Hutcha Sriplung, Donsuk Pongnikorn, Shama Virani, Surichai Bilheem, Udomlak Chaisaengkhaum, Puttachart Maneesai, Narate Waisri, Chirapong Hanpragopsuk, Panrada Tansiri, Varunee Khamsan, Malisa Poungsombat, Aumnart Mawoot, Imjai Chitapanarux
Objectives: This study was conducted to determine incidence trends of female breast cancer according to age groups and to predict future change in Chiang Mai women through 2028. Method: Data were collected from all hospitals in Chiang Mai in northern Thailand, from 1989 through 2013, and used to investigate effects of age, year of diagnosis (period) and year of birth (cohort) on female breast cancer incidences using an age-period-cohort model. This model features geometric cut trends to predict change by young (<40 years), middle-aged (40-59) and elderly (≥60) age groups...
May 1, 2017: Asian Pacific Journal of Cancer Prevention: APJCP
https://www.readbyqxmd.com/read/28606920/single-cell-dynamics-determines-response-to-cdk4-6-inhibition-in-triple-negative-breast-cancer
#11
Nicholas C Turner, Uzma Asghar, Alexis R Barr, Ros Cutts, Matthew Beaney, Irina S Babina, Deepak Sampath, Jennifer Giltnane, Jennifer A Lacap, Lisa Crocker, Amy Young, Alex Pearson, Maria Teresa Herrera-Abreu, Chris Bakal
Purpose: Triple negative breast cancer (TNBC) is a heterogeneous subgroup of breast cancer that is associated with a poor prognosis. We evaluated the activity of CDK4/6 inhibitors across the TNBC subtypes, and investigated mechanisms of sensitivity. <p>Experimental design: A panel of cell lines representative of TNBC were tested for in vitro and in vivo sensitivity to CDK4/6 inhibition. A fluorescent CDK2 activity reporter was used for single cell analysis in conjunction with time-lapse imaging.</p> <p>Results: The luminal androgen receptor (LAR) subtype of TNBC was highly sensitive to CDK4/6 inhibition both in vitro [p<0...
June 12, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28603694/estrogen-effects-on-the-mammary-gland-in-early-and-late-life-and-breast-cancer-risk
#12
REVIEW
Genevieve Victoria Dall, Kara Louise Britt
A woman has an increased risk of breast cancer if her lifelong estrogen exposure is increased due to an early menarche, a late menopause, and/or an absence of childbearing. For decades, it was presumed that the number of years of exposure drove the increased risk, however, recent epidemiological data have shown that early life exposure (young menarche) has a more significant effect on cancer risk than late menopause. Thus, rather than the overall exposure it seems that the timing of hormone exposure plays a major role in defining breast cancer risk...
2017: Frontiers in Oncology
https://www.readbyqxmd.com/read/28603643/assessing-the-usefulness-and-acceptability-of-a-low-health-literacy-online-decision-aid-about-reproductive-choices-for-younger-women-with-breast-cancer-the-alliance-pilot-study-protocol
#13
Michelle Peate, Sian Karen Smith, Victoria Pye, Alice Hucker, Catharyn Stern, Lesley Stafford, Catherine Oakman, Laura Chin-Lenn, Kerry Shanahan, Nipuni Ratnayake Gamage, Martha Hickey
BACKGROUND: Young women diagnosed with breast cancer may be confronted by many difficult decisions, especially around fertility preservation prior to commencing cancer treatment. The information to be conveyed is complex, and it may be difficult to weigh up the risks and benefits of the different fertility preservation options available. This complexity is compounded by the widespread low levels of literacy and health literacy in Australia, which may result in greater difficulties in understanding available health information and in decision-making...
2017: Pilot and Feasibility Studies
https://www.readbyqxmd.com/read/28601930/survival-improvement-in-hormone-responsive-young-breast-cancer-patients-with-endocrine-therapy
#14
Tae In Yoon, Ui-Kang Hwang, Eui Tae Kim, SaeByul Lee, Guiyun Sohn, Beom Seok Ko, Jong Won Lee, Byung Ho Son, Seonok Kim, Sei Hyun Ahn, Hee Jeong Kim
PURPOSE: We investigated the oncologic outcomes by intrinsic subtype and age in young breast cancer patients and whether survival differences were related to treatment changes over time. METHODS: A retrospective analysis was performed on 9633 invasive breast cancer patients treated at Asan Medical Center from January 1989 to December 2008. We also enrolled a matched cohort adjusting for tumor size, lymph node metastasis, subtypes, and tumor grade. Patients aged <35 years were included in the younger group (n = 602) and those aged ≥35 years were included in the older group (n = 3009)...
June 10, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28599788/nr1d1-enhances-oxidative-dna-damage-by-inhibiting-parp1-activity
#15
Na-Lee Ka, Tae-Young Na, Mi-Ock Lee
Cancer cells exhibit an elevated intracellular level of reactive oxygen species (ROS) because of their accelerated metabolism, mitochondrial dysfunction, and antioxidant deficit. The oxidative stress in cancer cells may provide clinical benefits, which can be associated with a better response to anticancer therapies. Therefore, identifying the regulatory pathway of oxidative stress in cancer cells is important in the development of therapeutic targets that enhance sensitivity to ROS-generating anticancer therapies...
June 6, 2017: Molecular and Cellular Endocrinology
https://www.readbyqxmd.com/read/28598691/development-of-68-ga-scn-dota-capsaicin-as-an-imaging-agent-targeting-apoptosis-and-cell-cycle-arrest-in-breast-cancer
#16
Jun Young Lee, Sang-Yeun Lee, Gun Gyun Kim, Min Goo Hur, Seung Dae Yang, Jeong-Hoon Park, Sang Wook Kim
(68)Ga-labeled capsaicin using a DOTA (1,4,7,10-tetraazocyclododecane-N,N',N″,N'″-tetraacetic acid) derivative [(68)Ga-SCN-Benzyl(Bn)-DOTA-capsaicin] was studied for the diagnosis of breast cancers, such as MCF-7 and SK-BR-3. The standard compound, (69)Ga-SCN-Bn-DOTA-capsaicin, was also prepared and characterized by spectroscopic analysis. The binding affinity of (68)Ga-SCN-Bn-DOTA-capsaicin was evaluated by using breast cancer cell lines (MCF-7, SK-BR-3) and colon cancer cell (CT-26); the biodistribution was carried out by using MCF-7-bearing nude mice, after which the positron emission tomography (PET) images were obtained at different time intervals (15-120 minutes)...
June 2017: Cancer Biotherapy & Radiopharmaceuticals
https://www.readbyqxmd.com/read/28598289/subtype-specific-radiation-response-and-therapeutic-effect-of-fas-death-receptor-modulation-in-human-breast-cancer
#17
Chen-Ting Lee, Yingchun Zhou, Kingshuk Roy-Choudhury, Sharareh Siamakpour-Reihani, Kenneth Young, Peter Hoang, John P Kirkpatrick, Jen-Tsan A Chi, Mark W Dewhirst, Janet K Horton
Breast cancer is the most common malignancy diagnosed among women and represents a heterogeneous group of subtypes. Radiation therapy is a critical component of treatment for breast cancer patients. However, little is known about radiation response among these intrinsic subtypes. In previous studies, we identified a significant induction of FAS after irradiation in biologically favorable breast cancer patients and breast cancer cell lines. Here, we expanded our study and investigated radiation response in a mouse model of breast cancer...
June 9, 2017: Radiation Research
https://www.readbyqxmd.com/read/28595511/breast-cancer-in-systemic-lupus-erythematosus-sle-receptor-status-and-treatment
#18
K Chan, A E Clarke, R Ramsey-Goldman, W Foulkes, B Tessier Cloutier, M B Urowitz, D Gladman, O Nived, J Romero-Diaz, M Petri, E Ginzler, P R Fortin, S C Bae, D J Wallace, E H Yelin, S Bernatsky
Objective There is a decreased risk of breast cancer in systemic lupus erythematosus (SLE) versus the general population; little is known regarding the receptor status of breast cancers in SLE, or treatment. Methods Breast cancer cases occurring after SLE diagnosis were ascertained through linkage with tumor registries. We determined breast cancer positivity for estrogen receptors (ER), progesterone receptors (PR), and/or Human Epidermal Growth Factor Receptor 2 (HER2), as well as cancer treatment. Results We obtained information on ER, PR, and/or HER2 status for 63 SLE patients with breast cancer...
January 1, 2017: Lupus
https://www.readbyqxmd.com/read/28592386/ct-p6-compared-with-reference-trastuzumab-for-her2-positive-breast-cancer-a-randomised-double-blind-active-controlled-phase-3-equivalence-trial
#19
Justin Stebbing, Yauheni Baranau, Valeriy Baryash, Alexey Manikhas, Vladimir Moiseyenko, Giorgi Dzagnidze, Edvard Zhavrid, Dmytro Boliukh, Daniil Stroyakovskii, Joanna Pikiel, Alexandru Eniu, Dmitry Komov, Gabriela Morar-Bolba, Rubi K Li, Andriy Rusyn, Sang Joon Lee, Sung Young Lee, Francisco J Esteva
BACKGROUND: CT-P6 is a proposed biosimilar to reference trastuzumab. In this study, we aimed to establish equivalence of CT-P6 to reference trastuzumab in neoadjuvant treatment of HER2-positive early-stage breast cancer. METHODS: In this randomised, double-blind, active-controlled, phase 3 equivalence trial, we recruited women aged 18 years or older with stage I-IIIa operable HER2-positive breast cancer from 112 centres in 23 countries. Inclusion criteria were an Eastern Cooperative Oncology Group performance status score of 0 or 1; a normal left ventricular ejection fraction of at least 55%; adequate bone marrow, hepatic, and renal function; at least one measureable lesion; and known oestrogen and progesterone receptor status...
June 2, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28591710/selective-inhibitors-of-nuclear-export-sine-compounds-block-proliferation-and-migration-of-triple-negative-breast-cancer-cells-by-restoring-expression-of-arrdc3
#20
Young Hwa Soung, Trinayan Kashyap, Thalia Nguyen, Garima Yadav, Hua Chang, Yosef Landesman, Jun Chung
Arrestin-related domain-containing protein-3 (ARRDC3) is one of 6 mammalian arrestins, which suppresses metastasis by inducing degradation of phosphorylated β2-adrenergic receptor (β2 AR) and integrin β4 (ITG β4). Our previous studies demonstrated that expression of ARRDC3 is epigentically silenced in Triple Negative Breast Cancer (TNBC) cells, and the forced expression of ARRDC3 significantly reduced the invasive potential of TNBC cells. In the current study, we found that Selective Inhibitors of Nuclear Export (SINE) compounds (KPT-185 and selinexor (KPT-330)) restore ARRDC3 expression in TNBC cell lines (MDA-MB-231 and MDA-MB-468) at both the mRNA and protein level in a dose and time course dependent manner...
May 18, 2017: Oncotarget
keyword
keyword
69608
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"